Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2435401 | 0.97 | L3MBTL3 (0.48) | L3MBTL3L3MBTL1KDM4EALDH1A1HRH3 | |
| SCHEMBL6464543 | 0.92 | HRH3 (0.46) | L3MBTL3L3MBTL1KDM4EALDH1A1HRH3 | |
| SCHEMBL5004073 | 0.91 | HRH3 (0.41) | L3MBTL3L3MBTL1KDM4EALDH1A1HRH3 | |
| SCHEMBL25672747 | 0.91 | L3MBTL3 (0.47) | L3MBTL3L3MBTL1KDM4EALDH1A1HRH3 | |
| SCHEMBL14528417 | 0.90 | L3MBTL3 (0.43) | L3MBTL3L3MBTL1KDM4EALDH1A1HRH3 | |
| SCHEMBL14907095 | 0.88 | L3MBTL3 (0.49) | L3MBTL3L3MBTL1KDM4EALDH1A1HRH3 | |
| SCHEMBL24770316 | 0.85 | KDM4E (0.36) | L3MBTL3L3MBTL1KDM4EALDH1A1HRH3 | |
| SCHEMBL1439628 | 0.85 | KDM4E (0.36) | L3MBTL3L3MBTL1KDM4EALDH1A1HRH3 | |
| SCHEMBL16877337 | 0.85 | L3MBTL3 (0.43) | L3MBTL3L3MBTL1KDM4EALDH1A1HRH3 | |
| SCHEMBL18207732 | 0.85 | SMN1; SMN2 (0.48) | L3MBTL3L3MBTL1KDM4EALDH1A1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114761404-B | Substituted bicyclic heteroaryl compounds | 百时美施贵宝公司 | 2025-02-21 | — | — | CN | claimed |
| US-11420970-B1 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NOVARTIS AG (CH) | 2022-08-23 | — | — | US | claimed |
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | PMV PHARMACEUTICALS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12485123-B2 | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250319063-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2025-10-16 | — | — | US | disclosed |
| US-12428406-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-12419880-B2 | Companion diagnostic tool for mutant p53 reactivating compounds | PMV PHARMACEUTICALS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| CN-114761404-B | Substituted bicyclic heteroaryl compounds | 百时美施贵宝公司 | 2025-02-21 | — | — | CN | disclosed |
| US-20240269126-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV PHARMACEUTICALS, INC. | 2024-08-15 | — | — | US | disclosed |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| US-7521457-B2 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-21 | — | — | US | disclosed |
| CN-1193021-C | Process for producing tetrahydropyranyl-4-sulfonate and 4-aminotetrahydropyran compound | UBE INDUSTRIES (JP) | 2005-03-16 | — | — | CN | disclosed |
| EP-1247807-B1 | PROCESSES FOR PRODUCING TETRAHYDROPYRANYL-4-SULFONATE AND 4-AMINOTETRAHYDROPYRAN COMPOUND | UBE INDUSTRIES (JP) | 2004-04-28 | — | — | EP | disclosed |
| US-6653489-B2 | Reacting 3-buten-1-ol with a formaldehyde compound and an organic sulfonic acid | UBE INDUSTRIES, INC. (JP) | 2003-11-25 | — | — | US | disclosed |
| CN-1409707-A | Process for producing tetrahydropyranyl-4-sulfonate and 4-aminotetrahydropyran compound | UBE INDUSTRIES (JP) | 2003-04-09 | — | — | CN | disclosed |
| US-20030004359-A1 | Processes for producing tetrahydropyranyl-4-sulfonates and 4-aminotetrahydropyran compound | UBE INDUSTRIES, LTD. (JP) | 2003-01-02 | — | — | US | disclosed |
| EP-1247807-A1 | PROCESSES FOR PRODUCING TETRAHYDROPYRANYL-4-SULFONATE AND 4-AMINOTETRAHYDROPYRAN COMPOUND | Ube Industries, Ltd. (JP) | 2002-10-09 | — | — | EP | disclosed |
| EP-0934932-A1 | QUINOLINE DERIVATIVES AND PSYCHOTROPIC AGENT | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1999-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004359-A1 | Processes for producing tetrahydropyranyl-4-sulfonates and 4-aminotetrahydropyran compound | HPD, DHPS, FDPS | L3MBTL3 4800/4885L3MBTL1 4571/4885KDM4E 874/4885 |
| US-12485123-B2 | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists | TLR7, TLR1, TLR9 | L3MBTL3 2925/4885L3MBTL1 2808/4885KDM4E 2165/4885 |
| US-12428406-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | L3MBTL3 188/4885L3MBTL1 183/4885KDM4E 2994/4885 |
| US-11420970-B1 | Piperidinyl-methyl-purineamines as NSD2 inhibitors and anti-cancer agents | NSD2, NSD1, NSD3 | L3MBTL3 3082/4885L3MBTL1 2456/4885KDM4E 769/4885 |
| US-20250319063-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | TP53, TP53BP1, KRAS | L3MBTL3 166/4885L3MBTL1 163/4885KDM4E 3022/4885 |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | L3MBTL3 1217/4885L3MBTL1 849/4885KDM4E 1758/4885 |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, BRCA1 | L3MBTL3 120/4885L3MBTL1 180/4885KDM4E 385/4885 |
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | TP53, TP53BP1, ERCC2 | L3MBTL3 524/4885L3MBTL1 443/4885KDM4E 3295/4885 |
| US-20240269126-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | TP53, KRAS, TP53BP1 | L3MBTL3 257/4885L3MBTL1 244/4885KDM4E 3164/4885 |
| US-20260098032-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, MDM2 | L3MBTL3 107/4885L3MBTL1 88/4885KDM4E 1371/4885 |
| US-12419880-B2 | Companion diagnostic tool for mutant p53 reactivating compounds | TP53, TP53BP1, KRAS | L3MBTL3 216/4885L3MBTL1 191/4885KDM4E 3177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.